Alyeska Investment Group
KYMR icon

Alyeska Investment Group’s Kymera Therapeutics KYMR Stock Holding History

Alyeska Investment Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.7M Sell
276,455
-66,243
-19% -$5.69M 0.08% 267
2026
Q1 		$28.5M Sell
342,698
-29,191
-8% -$2.31M 0.08% 267
2025
Q4 		$28.9M Sell
371,889
-243,202
-40% -$16.4M 0.08% 260
2025
Q3 		$34.8M Buy
615,091
+565,091
+1,130% +$25.5M 0.11% 215
2025
Q2 		$2.18M Buy
+50,000
New +$1.72M 0.01% 479
2022
Q2 		– Sell
-183,750
Closed -$7.78M – 620
2022
Q1 		$7.78M Buy
183,750
+57,457
+45% +$2.43M 0.09% 237
2021
Q4 		$8.02M Buy
126,293
+1,293
+1% +$75.3K 0.09% 212
2021
Q3 		$7.34M Buy
+125,000
New +$7.25M 0.09% 255

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Alyeska Investment Group's KYMR Position: Q2 2026 in Review

Alyeska Investment Group reduced its Kymera Therapeutics (KYMR) stake by 19% in Q2 2026, selling an estimated $5.69M and leaving 276,455 shares worth $31.7M. The position accounts for 0.08% of the portfolio, ranked #267.

Alyeska Investment Group first reported a position in KYMR in Q3 2021 and has held it in 8 quarters since. The position peaked at $34.8M in Q3 2025. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Alyeska Investment Group held 276,455 shares of Kymera Therapeutics worth $31.7M as of Q2 2026.
  • Alyeska Investment Group sold 66,243 Kymera Therapeutics shares in Q2 2026, an estimated $5.69M.
  • Kymera Therapeutics made up 0.08% of Alyeska Investment Group's portfolio in Q2 2026, its #267 holding.
  • Alyeska Investment Group first reported a position in Kymera Therapeutics in Q3 2021 and has held it in 8 quarters since.
  • Alyeska Investment Group's Kymera Therapeutics position peaked at $34.8M in Q3 2025.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.